Elite Pharmaceuticals Granted New Patent for Abuse Deterrent Technology
May 31, 2017 07:30 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., May 31, 2017 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB:ELTP) announced today the issuance of European Patent No. 1615623 titled...
Elite Pharmaceuticals Reports Positive Topline Results from a Pivotal Bioequivalence Study
May 30, 2017 08:42 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., May 30, 2017 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB:ELTP) today reported positive topline results from pivotal bioequivalence studies...
Elite Pharmaceuticals’ SequestOx™ Study Results Expected in July
May 25, 2017 07:00 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., May 25, 2017 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB:ELTP), today announced that top-line results for its reformulated SequestOx™ study are...
Elite Pharmaceuticals Acquires Trimipramine ANDA
May 22, 2017 16:11 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., May 22, 2017 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB:ELTP), today announced the acquisition of an approved and currently marketed...
Elite Pharmaceuticals, Inc. Initiates Pivotal Bioequivalence Fed Study for Reformulated SequestOx™
March 13, 2017 08:00 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., March 13, 2017 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB:ELTP), announced today that it has initiated pharmacokinetic testing of its...
Elite Pharmaceuticals, Inc. Reports Results for Third Quarter of Fiscal Year 2017
February 09, 2017 16:34 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Feb. 09, 2017 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB:ELTP), announced results for the quarter ended December 31, 2016, the third quarter...
Elite Pharmaceuticals, Inc. to Host Conference Call to Discuss 3rd Quarter 2017 Financial Results on February 13, 2017
February 07, 2017 08:00 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Feb. 07, 2017 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCQB:ELTP), a specialty pharmaceutical company developing a pipeline of abuse-deterrent...
Elite Reports On SequestOx™ FDA End-of-Review Meeting
January 23, 2017 08:18 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Jan. 23, 2017 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB:ELTP) today reported the Company received official minutes from its December 21, 2016...
Elite Pharmaceuticals Reports Positive Topline Results from a Pivotal Bioequivalence Study for a Generic OxyContin®
January 17, 2017 08:00 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J, Jan. 17, 2017 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB:ELTP) today reported positive topline results from a pivotal bioequivalence fed study...
Elite Provides Update on SequestOx™ New Drug Application
December 22, 2016 12:31 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Dec. 22, 2016 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB:ELTP) today announced the Company met with the U.S. Food and Drug Administration (the...